Replies to post #92117 on Biotech Values

[DonShimoda]

bladerunner, this is from one of the filings "approximately $27 million in milestone payments related to the start of Phase 3 clinical trials of ridaforolimus originally expected to be received in the fourth quarter of 2009 under the ridaforolimus collaboration agreement with Merck would likely be delayed until the first or second quarter of 2010."

So, I do think there have been disagreements beyond the decision to not move forward with the herceptin/rida breast cancer Phase 3 trial. (although I think that was partly influenced by competitive factors). I'm not saying that MRK has cold feet....quite the contrary as they recently started a new rida trial in Japan.